News
AKYA
2.360
+7.76%
0.170
Weekly Report: what happened at AKYA last week (0603-0607)?
Weekly Report · 2d ago
Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Akoya Biosciences (NASDAQ:AKYA) is a life sciences technology company. The company has a 12-month price target of $6.5. It has been downgraded by 4 analysts in the past three months. The firm's revenue growth lags behind its peers in the health care sector.
Benzinga · 06/03 14:00
Akoya Biosciences Is Maintained at Overweight by Morgan Stanley
Dow Jones · 06/03 13:15
Akoya Biosciences Price Target Cut to $4.00/Share From $8.00 by Morgan Stanley
Dow Jones · 06/03 13:15
Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $4
Benzinga · 06/03 13:05
Weekly Report: what happened at AKYA last week (0527-0531)?
Weekly Report · 06/03 09:01
Buy Rating on Akoya Biosciences: Temporary Setbacks, Growth Potential, and an Attractive Entry Point
TipRanks · 06/03 01:15
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now
Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO Brian McKelligon's total compensation is 99% above the industry average. The company's three-year loss to shareholders was 89% while its EPS grew by 56% over the past three years. Akoya B biosciences' Annual General Meeting is scheduled for the 4th of June. Despite positive earnings growth in the past few years, the share price hasn't tracked the fundamental performance of the company. We look at why shareholders should be cautious of Akoya's CEO pay. The company has a CEO compensation of US$ and is set to meet in June.
Simply Wall St · 05/29 11:38
Weekly Report: what happened at AKYA last week (0520-0524)?
Weekly Report · 05/27 09:01
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses. The healthcare industry is facing immense headwinds.
Seeking Alpha · 05/23 13:17
Weekly Report: what happened at AKYA last week (0513-0517)?
Weekly Report · 05/20 09:00
Analysts’ Top Healthcare Picks: Akoya Biosciences (AKYA), Rubicon Organics (ROMJF)
TipRanks · 05/17 12:20
AKOYA BIOSCIENCES INC <AKYA.O>: STEPHENS CUTS TARGET PRICE TO $6 FROM $7
Reuters · 05/15 05:12
JAN, MTC and PROK among mid-day movers
On the Move JAN, MTC and PROK among mid-day movers. Faraday Future Intelligent Electric (FFIE) and AMC Entertainment Holdings (AMC) gain. Augmedix (AUGX) is one of many companies to lose ground.
Seeking Alpha · 05/14 17:44
Akoya Biosciences Price Target Cut to $6.00/Share From $10.00 by Canaccord Genuity
Dow Jones · 05/14 17:41
Akoya Biosciences Is Maintained at Buy by Canaccord Genuity
Dow Jones · 05/14 17:41
Canaccord Genuity Maintains Buy on Akoya Biosciences, Lowers Price Target to $6
Benzinga · 05/14 17:32
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Alibaba Group Holding Limited fell sharply during Tuesday's session following mixed first-quarter financial results. The e-commerce giant reported revenue growth of 7% year-on-year but missed the analyst consensus estimate of $. Cheetah Net Supply Chain Service Inc. Shares jumped 136% to $ after a follow-on public offering.
Benzinga · 05/14 17:30
Akoya Biosciences Is Maintained at Buy by BTIG
Dow Jones · 05/14 17:12
Akoya Biosciences Price Target Cut to $6.00/Share From $9.00 by BTIG
Dow Jones · 05/14 17:12
More
Webull provides a variety of real-time AKYA stock news. You can receive the latest news about Akoya Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AKYA
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).